Consolidated Statements of Operations (Unaudited) (USD $)	3 Months Ended		9 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Mar. 31, 2013	Mar. 31, 2012
Revenue	$ 10,379	$ 0	$ 10,379	$ 0
Operating expenses:
General and administrative (including stock-based compensation (Note 7))	969,503	861,571	4,390,257	5,649,626
Research and development (including stock-based compensation (Note 7))	53,259	34,810	139,578	133,304
Total operating expenses	1,022,762	896,381	4,529,835	5,782,930
Loss from operations	(1,012,383)	(896,381)	(4,519,456)	(5,782,930)
Other expense (income):
Interest expense	80,002	35,431	207,386	49,861
Interest income	(44)	(331)	(140)	(2,033)
	79,958	35,100	207,246	47,828
Net loss	(1,092,341)	(931,481)	(4,726,702)	(5,830,758)
Net loss attributable to the noncontrolling interest	1,466	1,360	4,257	15,634
Net loss attributable to Bion	(1,090,875)	(930,121)	(4,722,445)	(5,815,124)
Conversion inducement				(755,258)
Dividends on preferred stock	(1,000)	(1,875)	(3,917)	(153,300)
Net loss applicable to Bion's common stockholders	$ (1,091,875)	$ (931,996)	$ (4,726,362)	$ (6,723,682)
Net loss applicable to Bion's common stockholders per basic and diluted common share (in Dollars per share)	$ (0.06)	$ (0.06)	$ (0.27)	$ (0.44)
Weighted-average number of common shares outstanding:
Basic and diluted (in Shares)	17,476,779	16,145,128	17,197,996	15,134,477